FDA approves Novartis drug for rare blood disorder
The FDA has approved Novartis’ pill iptacopan for adults with paroxysmal nocturnal hemoglobinuria, or PNH, a rare disorder where the red blood cells break up early.
The pill will be branded as Fabhalta, Novartis announced Tuesday evening. Fabhalta’s entrance to the market will challenge AstraZeneca’s drugs Soliris and Ultomiris, which have been backbones of care for the disease and brought in $5.73 billion in sales last year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.